How weight-loss jabs are changing the way we spend money

"Weight-loss jabs are not only transforming people's bodies but also people's spending habits. Around 2.5 million people are currently estimated to be on the medications in the UK. The drugs, such as semaglutide marketed under names such as Wegovy, Ozempic and Rybelsus and tirzepatide, marketed under the name Mounjaro, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. Those who buy the injections, also known as GLP-1 receptor agonists, privately can end up spending hundreds of pounds a month for years."

"From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging."

Around 2.5 million people in the UK are estimated to be using GLP-1 weight-loss medications such as semaglutide (Wegovy, Ozempic, Rybelsus) and tirzepatide (Mounjaro). These drugs mimic the hormone regulating blood sugar, appetite and digestion and are often obtained privately at costs of hundreds of pounds per month. Rising popularity is changing household spending and consumer priorities. Major retailers and supermarkets are introducing GLP-1-friendly, portion-controlled, nutrient-rich food lines and weight-management ranges. Businesses across the food and retail sectors are adapting products and services to meet growing, long-term demand from this consumer group.

Read at www.independent.co.uk